

γ -Tocotrienol inhibits angiogenesis of human umbilical vein endothelial cell induced by cancer cell

Yang Li^{a,1}, Wen-Guang Sun^{b,1}, Hui-Kun Liu^a, Gui-Yun Qi^c, Qi Wang^a, Xiang-Rong Sun^a,
Bing-Qing Chen^{a,*}, Jia-Ren Liu^{a,d,*}

^aDepartment of Nutrition and Food Hygiene, Public Health College, Harbin Medical University, Harbin 150081, People's Republic of China

^bDepartment of Clinic Nutrition, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, People's Republic of China

^cDepartment of Laboratory, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, People's Republic of China

^dHarvard Medical School, Boston, MA 02115–5737, USA

Received 9 May 2010; received in revised form 20 September 2010; accepted 22 September 2010

Abstract

Antiangiogenic therapy mediated by food components is an established strategy for cancer chemoprevention. Growth factors play critical roles in tumor angiogenesis. A conditioned medium containing growth factors from human gastric adenocarcinoma SGC-7901 cell conditioned medium was used as an angiogenic stimulus in this study. The purpose of this study was to evaluate the inhibitory effect and possible mechanism of γ -tocotrienol on tumor angiogenesis. The results showed that γ -tocotrienol (10–40 $\mu\text{mol/L}$) significantly suppressed proliferation, migration and tube formation of human umbilical vein endothelial cells (HUVECs) induced by SGC-7901 cell conditioned medium in a dose-dependent manner. γ -Tocotrienol (800–1200 $\mu\text{g/egg}$) also inhibited new blood vessel formation on the growing chick embryo chorioallantoic membrane in a dose-dependent manner. Moreover, the inhibitory effects of γ -tocotrienol on HUVECs were correlated with inducing the apoptosis and arresting cell cycle at the G_0/G_1 phase at a dose of 40 $\mu\text{mol/L}$ γ -tocotrienol. In addition, γ -tocotrienol inhibited angiogenesis in HUVECs by down-regulation of β -catenin, cyclin D1, CD44, phospho-VEGFR-2 and MMP-9. The antiangiogenic effects of γ -tocotrienol on HUVECs may be attributable to regulation of Wnt signaling by decreasing β -catenin expression. Thus, our results suggest that γ -tocotrienol has a potential chemopreventive agent via antiangiogenesis.

© 2011 Elsevier Inc. All rights reserved.

Keywords: γ -Tocotrienol; Angiogenesis; HUVEC; Wnt signaling

1. Introduction

Angiogenesis, the formation of new blood vessels from a preexisting vascular bed, is of fundamental importance in several pathological states, such as tumor growth, diabetic retinopathy and rheumatic arthritis [1,2]. Tumor-induced angiogenesis is a pathological condition that results from aberrant development of normal angiogenesis. Angiogenesis is especially important for the development of tumor as the delivery of blood-borne nutrients to the tumor cells, which is essential for their survival [3], and for the spread of metastatic tumor cells [4]. Furthermore, angiogenesis

has been reported to have a close correlation with prognosis of solid tumors [5–7]. Due to the knowledge that a solid tumor cannot grow beyond a critical size of 1–2 mm^3 or metastasize without an adequate blood supply [8,9], tumor-associated angiogenesis can be effectively targeted as an anticancer therapeutic strategy [10–13].

Natural vitamin E is a mixture of two classes of compounds, tocopherols and tocotrienols. The differences between tocopherols and tocotrienols are that the former contains a saturated and phytyl tail, whereas the latter contains an unsaturated isoprenoid side chain. Although both tocopherols and tocotrienols have various biological effects, tocotrienols have also been reported to have an antiproliferative activity and to induce apoptosis in many kinds of malignant carcinoma cells, such as breast [14–18], colon [19,20], prostate [21] and hepatocarcinoma [22] cells. In our previous study, γ -tocotrienol induced human gastric adenocarcinoma SGC-7901 cell apoptosis through mitochondria-dependent apoptosis pathway and was associated with down-regulation of the Raf–ERK signaling pathway [23–25]. γ -Tocotrienol also induced human colon carcinoma HT-29 cell apoptosis in a dose-dependent manner [20]. Moreover, during the past decade, some evidence demonstrating the antiangiogenesis activity of tocotrienol has accumulated

* Corresponding authors. Bing-Qing Chen is to be contacted at Department of Nutrition and Food Hygiene, Public Health College, Harbin Medical University, Harbin 150081, People's Republic of China. Tel.: +86 451 8750 2961; fax: +86 451 8750 2885; Jia-Ren Liu, Harvard Medical School, Boston, MA 02115–5737, USA.

E-mail addresses: liyang820119@sohu.com (Y. Li), sunwenguang@54dr.com (W.-G. Sun), bingqingchen@sina.com (B.-Q. Chen), jia-ren.liu@childrens.harvard.edu (J.-R. Liu).

¹ Y.L. and W.-G.S. contributed equally to this work.

[2,26–30]. These results suggest that tocotrienol has potential use as a therapeutic dietary supplement for minimizing tumor angiogenesis. However, the inhibitory mechanism of tocotrienols on tumor-induced angiogenesis remains unclear. Thus, many approaches are needed to disclose how tocotrienol affects angiogenesis in a biological system. The objective of this study was to determine the effects of γ -tocotrienol on proliferation, migration and tube formation of human umbilical vein endothelial cells (HUVECs), the key steps of angiogenesis and the possible mechanisms of antiangiogenesis of γ -tocotrienol in HUVECs.

2. Materials and methods

2.1. Chemicals and reagents

3-[4,5-Dimethylthiazol-2,5-diphenyl tetrazolium bromide (MTT), α -tocopherol and Suramin sodium salt were purchased from Sigma Chemical (St. Louis, MO, USA). Purified γ -tocotrienol was purchased from Davos (Singapore). Cycle TEST PLUS DNA

reagents were purchased from BD Biosciences. Rabbit polyclonal antibody specific to β -actin was from Sigma Chemical. Rabbit polyclonal antibodies specific to MMP (matrix metalloproteinase)-9 (G657), cyclin D1 (SP4), CD44 (BA0321), β -catenin (sc-7199) and phospho-VEGFR-2 (Tyr1054) were bought from Cell Signaling (Danvers, MA, USA), NeoMarkers (Thermo Scientific, Fremont, CA, USA), Boster (Harbin, China), Santa Cruz (Santa Cruz, CA, USA) and Millipore (Billerica, MA, USA), respectively. A nuclear and cytoplasmic protein extraction kit (P0027) was bought from Beyotime (Jiang Su, China).

2.2. Cell culture

Human gastric adenocarcinoma SGC-7901 cell line was obtained from the Cancer Institute of the Chinese Academy of Medical Science (Beijing, China). SGC-7901 cells were cultured in RPMI-1640 containing 10% fetal bovine serum (FBS) (Life Technologies, Gaithersburg, MD, USA), 2 mmol/L L-glutamin, 100 U/ml of penicillin and 100 μ g/ml of streptomycin. HUVECs (Sciencell) were cultured in endothelial cell medium (ECM) supplemented with 5% FBS, 1% endothelial cell growth supplement and 1% penicillin/streptomycin solution. The cell cultures were maintained at 37°C in a humidified atmosphere of 5% CO₂. Confluent HUVECs (passages 5–8) were used in the experiment.




Fig. 1. Effect of γ -tocotrienol on proliferation of HUVECs induced by SGC-7901-CM. SGC-7901-CM: SGC-7901 cells (~90% confluent) were washed with serum-free RPMI-1640 and incubated in RPMI-1640 medium containing 2% FBS. After 24 h, SGC-7901-CM was collected and centrifuged at 1000 rpm for 10 min. The cell proliferative effects were determined by MTT assay. HUVECs were seeded in 96-well plates (5×10^3 cells/well) and treated with different concentrations of γ -tocotrienol for (A) 12 h, (B) 24 h and (C) 48 h. Each concentration was repeated in four wells ($n=4$). * $P < .05$ and ** $P < .01$, compared with SGC-7901-CM-only treatment.




Fig. 2. Morphological changes of apoptosis were observed in SGC-7901-CM-induced HUVECs induced by γ -tocotrienol. Characteristics of apoptosis observed were chromatin condensation and margination, cell blebbing and vacuoles in HUVECs after treatment with 40 $\mu\text{mol/L}$ γ -tocotrienol for 48 h (C and D), in comparison with the cell without SGC-7901-CM (A) and SGC-7901-CM-only treatment for 48 h (B).

2.3. Preparation of SGC-7901 cell conditioned medium

SGC-7901 cell conditioned medium (SGC-7901-CM) was used as an angiogenic stimulus in the experiments. SGC-7901 cells (approximately 90% confluent) were washed with serum-free RPMI-1640 and incubated in the RPMI-1640 medium containing 2% FBS. After 24 h, SGC-7901-CM was collected, centrifuged at 1000 rpm for 10 min and stored at -30°C until used.

2.4. Cell proliferation assay

The effect of γ -tocotrienol on cell proliferation was determined with the MTT assay [31,32]. Briefly, HUVECs were plated in a 96-well plate at 5×10^3 cells/well. After 24 h, cells were treated with 100 μl of culture medium (containing 1% FBS with 0–50 $\mu\text{mol/L}$ γ -tocotrienol) and then 100 μl of SGC-7901-CM was added to each well. Four replicates were employed in each dose. After incubation for 12, 24 and 48 h, cell proliferation was determined. Twenty microliters of 10 mg/ml of MTT solution in phosphate-buffered saline (PBS) was added to each well and incubated for 4 h. After careful removal of the medium, 200 μl of dimethyl sulfoxide was added to each well, and the plate was then shaken until the crystals were solubilized. The absorbance was recorded on a microplate reader (Elx800 Universal Microplate Reader, Bio-Tek Instruments) at a wavelength of 570 nm.

2.5. Transmission electron microscopy

HUVECs were harvested from the negative control group, SGC-7901-CM-treated group and γ -tocotrienol-treated group (40 $\mu\text{mol/L}$, 48 h). The cells were washed with cold PBS, and then cells were fixed with 4% glutaraldehyde in PBS overnight at 4°C . After fixation with 1% OsO_4 in cacodylate buffer for 1 h at 4°C , cell pellets were dehydrated in graded ethanol solutions and embedded in Epon 812. Ultrathin sections of pellet were counterstained with acetate and lead citrate. The slides were observed under a transmission electron microscope [32].

2.6. Cell cycle analysis

HUVECs were harvested, washed three times with cool PBS, fixed with 70% cool ethanol for 2 h and stained with propidium iodide mixture (Cycle TEST PLUS DNA Reagent Kit). For each treatment, at least 2×10^4 cells were analyzed using a FACSort flow cytometer (BD Biosciences). The proportions at the G_0/G_1 , S and G_2/M phases were estimated using ModFit LT analysis software.

2.7. Cell migration assay

The trans-well cell culture chambers (Corning Costar 3422, Corning, Cambridge, MA, USA) were used for cell migration assay [33]. The membrane was coated with




Fig. 3. Cell cycle distributions in SGC-7901-CM-induced HUVECs treated with (B) 0 $\mu\text{mol/L}$ γ -tocotrienol and (C) 40 $\mu\text{mol/L}$ γ -tocotrienol and (A) in cells without SGC-7901-CM were analyzed by flow cytometry. (D) Summary of results. * $P < .05$, compared with 0 $\mu\text{mol/L}$ γ -tocotrienol (B).

a thin layer of ECM gel (Sigma Chemical). SGC-7901-CM was added into the lower chamber. Trypsin-harvested HUVECs (2×10^5 cells) were suspended in ECM containing 1% FBS with 0, 10, 20 and 40 $\mu\text{mol/L}$ γ -tocotrienol and then added into the upper chamber. After 24 h of incubation at 37°C, the non-migrated cells were removed from the upper surface of the membrane by wiping with a cotton swab. The membrane was then fixed with methanol for 15 min and then stained with hematoxylin and eosin. The stained cells were observed through a phase-contrast microscope (Nikon Company, Japan). The number of migrated cells was counted in three randomly selected microscopic fields [34].

2.8. Tube formation assay

Culture (24-well) plates were coated with 0.3 ml of ECM gel and incubated at 37°C for 4 h for solidification [25,35]. Trypsin-harvested HUVECs were treated with γ -tocotrienol under two conditions. First, HUVECs were suspended in 0.5 ml of ECM containing 1% FBS with 0, 10, 20 or 40 $\mu\text{mol/L}$ γ -tocotrienol and then were mixed with 0.5 ml of SGC-7901-CM. After incubation for 24 h, cells were fixed and photographed. Second, HUVECs were cultured in 0.5 ml of ECM (1% FBS) and 0.5 ml of SGC-7901-CM for 12 h. After incubation, cells were treated with γ -tocotrienol and incubated for another 12 h. The cells were fixed and photographed.

2.9. Chick chorioallantoic membrane (CAM) assay

α -Tocopherol and γ -tocotrienol were dissolved in soybean oil. A pellet of methylcellulose (Sigma Chemical) impregnated with 20 μl of α -tocopherol (60 g/L), γ -tocotrienol (20, 40 and 60 g/L), soybean oil (negative control) or Suramin sodium salt (positive control) was placed on the CAM surface of 7-day-old chick embryos. The embryos were incubated for 2 days at 37°C in a humidified incubator, after which the chorioallantois was fixed. Inhibition of angiogenesis was determined by the number of classes of blood vessel [36].

2.10. Immunofluorescence

HUVECs from the negative control group, SGC-7901-CM-treated group and γ -tocotrienol-treated group (20 and 40 $\mu\text{mol/L}$ for 48 h) were fixed with 4% paraformaldehyde for 15 min and washed with PBS. The cells were permeabilized with 0.1% Triton X-100 for 5 min and blocked for 30 min at room temperature with 1% bovine serum albumin (BSA). The cells were incubated with anti- β -catenin antibody overnight at 4°C. Cells were rinsed in PBS, incubated with fluorescein-conjugated AffiniPure goat anti-rabbit IgG (ZF-0311, ZSGB-Bio) for 1 h at room temperature and then covered with DAPI (C1002, Beyotime). Images were analyzed using an Olympus immunofluorescence microscope (Olympus Company, Japan).




Fig. 4. Effect of γ -tocotrienol on HUVEC migration induced by SGC-7901-CM. The trans-well cell culture chambers coated with ECM gel on the surface were used for cell migration assay. SGC-7901-CM was placed in the lower chamber (except A). Trypsin-harvested HUVECs (2×10^5) were suspended in ECM containing 1% FBS and 0 (B), 10 (C), 20 (D) and 40 (E) $\mu\text{mol/L}$ γ -tocotrienol, and they were then added into the upper chamber. After incubation at 37°C for 24 h, the non-migrated cells were removed from the upper surface of the membrane by wiping with a cotton swab. Cells on the lower side were stained with hematoxylin and eosin. The number of cells was randomly counted using a microscope ($\times 200$). The experiment was set up in independent triplicates ($n=3$). (F) Summary of results. * $P<.05$, compared with 0 $\mu\text{mol/L}$ γ -tocotrienol (B).

2.11. Western blot analysis

SGC-7901-CM-induced HUVECs in different treatment groups (0, 10, 20 and 40 $\mu\text{mol/L}$) were incubated for 48 h. Cellular protein was prepared from HUVECs. The protein concentrations of each sample were determined using a nucleic acid and protein analyzer (DU 640, Beckman) according to the manufacturer's instructions. For

Western blotting, 50–80 μg of total protein was resolved over 10% or 12% polyacrylamide gels and transferred to a nitrocellulose membrane. The membrane was blocked in blocking buffer [1% BSA and 1% Tween-20 in 20 mM Tris-buffered saline (TBST), pH 7.6] for 1 h at 37°C in a hybridization oven (Amersham Life Science, Little Chalfont, Bucks, UK), incubated with appropriate monoclonal or polyclonal primary antibody in blocking buffer for 2 h at 37°C or overnight at 4°C. The membrane was




Fig. 5. Effect of γ -tocotrienol on tube formation of HUVECs induced by SGC-7901-CM. I: HUVECs (5×10^4) were suspended in 1.0 ml ECM containing 1% FBS (A); HUVECs were plated in 0.5 ml of ECM containing 1% FBS and 0 $\mu\text{mol/L}$ γ -tocotrienol (B), 10 $\mu\text{mol/L}$ γ -tocotrienol (C), 20 $\mu\text{mol/L}$ γ -tocotrienol (D) and 40 $\mu\text{mol/L}$ γ -tocotrienol (E) and were then mixed with 0.5 ml of SGC-7901-CM. After incubation for 24 h, HUVECs were fixed and photographed. II: HUVECs were cultured in 0.5 ml of ECM (1% FBS) and 0.5 ml of SGC-7901-CM (A) for 12 h. After incubation, cells were treated with 40 $\mu\text{mol/L}$ γ -tocotrienol (B) and then continued to incubate for 12 h; cells were then fixed and photographed.




Fig. 6. Effect of γ -tocotrienol on the blood vessel formation of the CAM. A pellet of methylcellulose impregnated with α -tocopherol (1200 μ g (B)), γ -tocotrienol (400 (C), 800 (D) and 1200 μ g (E)), soybean oil (negative control (A)) or Suramin sodium salt (positive control (F)) was placed on the CAM surface of 7-day-old chick embryos and incubated for 2 days. The CAM was fixed and photographed. The most pyknic blood vessel was presumed as class I. Blood vessel separated from class I was called class II. The class III blood vessel separated from class II. The angiogenic response was evaluated by the number of classes of blood vessel ($n=10$). The results are summarized in Table 1.

washed with TBST three times (5 min each time) followed by incubation with secondary antibody at 37°C for 1 h. The membrane was washed with TBS one time. The membrane was then incubated with alkaline phosphatase until an appropriate signal

Table 1
Effects of γ -tocotrienol on the formation of new blood vessels in CAM (mean \pm S.D., $n=10$)

Group	Class I	Class II	Class III
Soybean oil (A)	1.6 \pm 0.5	11.3 \pm 2.2	104.0 \pm 5.1
α -Tocopherol (B)	1.5 \pm 0.5	9.5 \pm 1.8	98.7 \pm 6.6
γ -Tocotrienol (C)	1.4 \pm 0.5	9.7 \pm 1.8	86.2 \pm 5.1**
γ -Tocotrienol (D)	1.3 \pm 0.5	8.5 \pm 1.5**	80.3 \pm 6.2**
γ -Tocotrienol (E)	1.3 \pm 0.5	7.9 \pm 1.2**	75.6 \pm 4.7**
Suramin sodium salt (F)	1.2 \pm 0.8	7.8 \pm 1.3**	41.8 \pm 3.9**

CAMs were treated with soybean oil control (A), 1200 μ g/egg α -tocopherol (B), 400 μ g/egg γ -tocotrienol (C), 800 μ g/egg γ -tocotrienol (D), 1200 μ g/egg γ -tocotrienol (E) and Suramin sodium salt as a positive control (F). After γ -tocotrienol or α -tocopherol treatment, CAM was fixed and photographed. The most pyknic blood vessel was presumed as class I. Blood vessel separated from class II was called class III. The class III blood vessel separated from class II. The angiogenic response was evaluated by the number of classes of blood vessel ($n=10$). ** $P<.01$, compared with soybean oil control (A).

level was obtained. The protein bands were detected with FluorChem Imaging System (Alpha Innotech, San Leandro, CA, USA).

2.12. Statistical analysis

Data were expressed as the mean \pm S.D. Each experiment was performed in triplicates. Differences were analyzed for significance using one-way ANOVA with Bonferroni post hoc multiple comparisons, used to assess the difference between independent groups. Statistical significance was set at $P<.05$ or $P<.01$, and all P values were unadjusted for multiple comparisons.

3. Results

3.1. Effect of γ -tocotrienol on proliferation of HUVECs

The inhibitory effect of γ -tocotrienol on proliferation of HUVECs was examined by MTT assay. The cells were treated with various concentrations (5, 10, 15, 20, 25, 30, 35, 40, 45 and 50 μ mol/L) of γ -tocotrienol for 12, 24 and 48 h. γ -Tocotrienol significantly inhibited cell proliferation of HUVECs in a time- and dose-dependent manner (Fig. 1). The median inhibiting concentrations (IC_{50}) of γ -tocotrienol for inhibition of HUVECs were 36.76 ± 1.28 and 23.34 ± 1.06 μ mol/L at 24 and 48 h, respectively.

3.2. Apoptosis on HUVECs induced by γ -tocotrienol

Morphological changes were observed with a transmission electron microscope in HUVECs treated with 40 μ mol/L γ -tocotrienol for 48 h. The cells showed evidently characteristic changes of apoptosis, including cytoskeletal disruption, cell shrinkage, chromatin condensation and margination of nucleus, cell blebbing, formation of apoptotic body and mitochondrial denaturation, such as swelling and disappearance of mitochondrial cristate in the γ -tocotrienol-treated cells (Fig. 2C and D). In addition, cells in the control group had the clear cell organs in cytoplasm, and mitochondrial cristate was also observed clearly (Fig. 2A and B). The cell cycle distribution of HUVECs treated with γ -tocotrienol was also determined by flow cytometry. As shown in Fig. 3, SGC-7901-CM-induced HUVECs treated with 40 μ mol/L γ -tocotrienol showed strong cell cycle arrest at the G_0/G_1 phase. The proportion at the G_0/G_1 phase ranged from $68.79\pm 2.35\%$ in untreated cells to $75.06\pm 2.73\%$ in treated cells ($P<.05$). A peak of apoptosis was found in HUVECs treated with 40 μ mol/L γ -tocotrienol.

3.3. γ -Tocotrienol inhibited HUVEC migration

Effect of γ -tocotrienol on migration in HUVECs induced by SGC-7901-CM was determined by the trans-well cell culture chamber coated with ECM gel on the surface. The numbers of migration cells with SGC-7901-CM were 336.7 ± 23.0 , 326.0 ± 19.1 , 296.7 ± 18.2 and 285.7 ± 20.5 in HUVECs treated with 0, 10, 20 and 40 μ mol/L γ -tocotrienol for 24 h, respectively. The number of migration cells without SGC-7901-CM was 320.7 ± 34.7 (Fig. 4). A dose response was observed in this study.

3.4. γ -Tocotrienol inhibited HUVEC tube formation

Effect of γ -tocotrienol on tubular morphogenesis in HUVECs induced by SGC-7901-CM was examined. HUVECs incubated with SGC-7901-CM showed an increase in the lengths and reticular formation of endothelial tubes in comparison with those without SGC-7901-CM. An inhibition of tube formation was observed in SGC-7901-CM-induced HUVECs treated with γ -tocotrienol in a dose-dependent manner (Fig. 5, I). In addition, γ -tocotrienol did not affect the luminal structure (Fig. 5, II). It seems that γ -tocotrienol inhibits capillary tube

formation, but it does not affect existing capillary tubes of HUVECs induced by SGC-7901-CM on ECM gel.

3.5. Inhibition of angiogenesis by γ -tocotrienol in vivo

We further examined the effect of γ -tocotrienol on angiogenesis using CAM assay. The results are shown in Fig. 6 and Table 1. γ -Tocotrienol significantly inhibited embryonic angiogenesis of CAM, resulting in a lower number of classes of blood vessel. γ -Tocotrienol also significantly inhibited classes II and III of blood vessel of CAM in a dose-dependent manner. No antiangiogenic activity was found in the α -tocopherol-treated group.

3.6. Wnt pathway protein expression

The inhibitory mechanism of γ -tocotrienol on tumor-induced angiogenesis was further investigated by immunofluorescence and Western blot. Considering the critical role of Wnt signaling in tumor angiogenesis, the effect of γ -tocotrienol on the Wnt pathway was examined. γ -Tocotrienol down-regulated the expression of β -catenin, which is the central player in Wnt signaling. In this study, γ -tocotrienol also down-regulated the expression of total β -catenin and nuclear β -catenin in a dose-dependent manner. γ -Tocotrienol promoted the translocation of β -catenin from cell nucleus to cell membrane (Fig. 7). In addition, γ -tocotrienol inhibited the expression




Fig. 7. Effect of γ -tocotrienol on β -catenin localization in SGC-7901-CM-induced HUVECs by immunofluorescence. HUVECs were suspended in 2.0 ml of ECM containing 1% FBS (A); HUVECs were plated in 1.0 ml of ECM (1% FBS) with 0 μ mol/L γ -tocotrienol (B), 20 μ mol/L γ -tocotrienol (C) and 40 μ mol/L γ -tocotrienol (D) and then were mixed with 1.0 ml of SGC-7901-CM. After incubation for 48 h, cells were fixed with 4% paraformaldehyde for 15 min and washed with PBS. Then, cells were permeabilized with 0.1% Triton X-100 for 5 min and blocked for 30 min at room temperature with 1% BSA and incubated with anti- β -catenin antibody overnight at 4°C. Cells were rinsed in PBS, incubated with anti-rabbit IgG/DyLight 488 for 1 h at room temperature and then covered with DAPI mounting medium. Images were analyzed using an Olympus immunofluorescence microscope.




Fig. 8. Expression of β -catenin, CD44, cyclin D1, MMP-9, phospho-VEGFR-2 and β -actin in SGC-7901-CM-induced HUVECs treated with different concentrations of γ -tocotrienol for 48 h. Proteins were separated on 10% or 12% SDS-PAGE gel, transferred to nitrocellulose membrane and probed with anti- β -catenin, anti-CD44, anti-cyclin D1, anti-MMP-9, anti-phospho-VEGFR-2 or anti- β -actin. The experiment was performed in triplicates. (A) No CM negative group; (B) CM negative group; (C) CM with 10 μ mol/L γ -tocotrienol; (D) CM with 20 μ mol/L γ -tocotrienol; (E) CM with 40 μ mol/L γ -tocotrienol. * P <.05, ** P <.01, compared with SGC-7901-CM-only treatment.

of cyclin D1 and CD44, which are involved in cell cycle progression and cell migration. γ -Tocotrienol also inhibited SGC-7901-CM-induced phospho-VEGFR-2 and MMP-9 expression (Fig. 8).

4. Discussion

Epidemiological and laboratory studies have shown that the consumption of vegetables, fruits and grains is associated with a low risk of cancer [37–42]. Many natural dietary phytochemicals found in fruits, vegetables, spices and tea have been shown to be protective against cancer in various animal models [38–40,42–44]. Tocotrienols have been shown to possess biological activity besides antioxidant activity, such as anticarcinogenic properties, which are evidenced mainly *in vivo* and *in vitro* [45]. Recently, tocotrienols have also been reported to have led to the induction of apoptosis in many various cancer cells, such as rat hepatoma dRLh-84 cells, human hepatoma Hep3B cells and human breast carcinoma MCF-7 cells [22,46,47]. γ -Tocotrienol has also been reported to have antitumor effects *in vivo*. γ -Tocotrienol feeding has been demonstrated to decrease tumor weight and to prolong the survival rate of C57BL female mice transplanted with melanoma [48]. Tocotrienol mixture (38% γ -tocotrienol, 22% α -tocotrienol and 12% δ -tocotrienol) significantly suppressed liver and lung carcinogenesis in C3H/HeN male mice [49]. Furthermore, it has been reported that accumulation is critical for antitumor activity of tocotrienol *in vivo* [50]. In our previous study,

γ -tocotrienol showed a significantly inhibitory effect on invasion and metastasis of SGC-7901 cells [34]. Moreover, tocotrienol at a low dose range inhibited proliferation, migration and tube formation of bovine aortic endothelial cells and HUVECs. These findings suggested that tocotrienols, but not tocopherols, have considerable potential as an angiogenesis inhibitor. In a previous study, the effects of δ -tocotrienol on antiangiogenesis would be associated with changes in phosphatidylinositol-3 kinase (PI3K)/PDK/Akt signaling and apoptosis induction in endothelial cells [28]. However, the activities of tocotrienol for tumor angiogenesis in HUVECs and the relationship among these cell signalings are not entirely understood.

Angiogenesis, the formation of new capillaries through sprouting, is the primary process responsible for tumor neovascularization. Angiogenesis normally involves a series of steps, including endothelial cell activation and breakdown of the basement membrane, followed by proliferation, migration and tube formation of the endothelial cells. This process depends on the balance between the effects of proangiogenic and antiangiogenic factors. Thus, SGC-7901-CM was used as the angiogenic stimulus. In our study, we demonstrated the inhibitory effect of γ -tocotrienol on tumor angiogenesis *in vitro* and *in vivo*. γ -Tocotrienol significantly inhibited proliferation, tube formation and migration in HUVECs. In addition, the cell cycle arrest and apoptosis induction were also observed in SGC-7901-CM-induced HUVECs. γ -Tocotrienol also inhibited the new blood vessel formation on the CAM. Moreover, δ -tocotrienol has also been reported to inhibit

the human colorectal adenocarcinoma cell medium (DLD-1-CM) and induced angiogenesis in nude mice [30]. In addition, once capillary tubes were formed, γ -tocotrienol did not affect the luminal structure, implying that γ -tocotrienol has no cytotoxicity on endothelial cells. It demonstrated that γ -tocotrienol may be safe as a candidate agent for chemoprevention of cancer.

Wnt signaling pathways play important roles in the regulation of cellular proliferation, differentiation, motility and morphogenesis [51–54]. Wnt signaling has a crosstalk with other signaling pathways regulating apoptosis, angiogenesis, invasion and metastasis [55]. In endothelial cells, Wnt signaling has been reported to increase cell proliferation [56] and to regulate migration and cell cycle progression [57]. Moreover, defects of yolk sac and placental angiogenesis in mice lacking the Frz5 gene directly demonstrate the involvement of Wnt signaling in vascular development [58]. β -Catenin is phosphorylated and subsequently ubiquitinated and degraded by the 26S proteasome system, and this degradation is initiated by phosphorylation at S45, T41, S37 and S33 at its NH₂-terminal region in normal cells [59]. Activation of Wnt signaling pathway leads to inhibition of GSK-3 β activity, resulting in deregulated accumulation of cytoplasmic β -catenin that can shift to nucleus and activates transcription of a series of genes, including cyclin D1, CD44, Cox-2, c-Myc, etc., by binding with T cell factors and lymphoid-enhancing factors [60,61]. Consequently, β -catenin has been regarded as a central player in Wnt signaling. As cell adhesion molecules play a role in cell–cell and cell–extracellular matrix adhesion and interactions, CD44 is involved in the process of tumor invasion and metastases. Moreover, CD44 might also be important in angiogenesis. Evidence confirms the involvement of CD44 in endothelial cell proliferation, migration and angiogenesis *in vitro* [62]. Cyclin D1, a known key regulator of cell proliferation, plays a critical role in cell cycle progression during mid G₁ by initiating the multistep process that leads to pRb inactivation [63]. In this study, γ -tocotrienol significantly inhibited expression of β -catenin in SGC-7901-CM-induced HUVECs. In addition, γ -tocotrienol significantly inhibited the expression of total β -catenin and nuclear β -catenin in SGC-7901-CM-induced HUVECs. γ -Tocotrienol also promoted the translocation of β -catenin from cell nucleus to cell membrane. Furthermore, γ -tocotrienol down-regulated the expression of cyclin D1 and CD44 in a dose-dependent manner. It indicated that the inhibitory effects of tocotrienol in HUVECs may be related to a decrease in the intracellular PI3K/PDK/Akt (Wnt) signaling protein activity. Thus, in the future, how γ -tocotrienol adjusts Wnt and PI3K/PDK/Akt signaling should be investigated.

VEGFRs are members of the receptor tyrosine kinase superfamily [64]. VEGFR-2 is considered to be the major mediator of the mitogenic, angiogenic and permeability-enhancing effects of VEGF and hence is a major target for antiangiogenic therapies. It is well known that VEGF induces HUVEC migration and tube formation through the phosphorylation of VEGFR-2, which is expressed on endothelial cells [65–67]. In our study, γ -tocotrienol inhibited phosphorylation of VEGFR-2 in SGC-7901-CM-induced HUVECs. It has been reported that inhibitor of Wnt signaling down-regulated VEGFR-2 messenger RNA and protein [68]. It becomes tempting to suggest the γ -tocotrienol may actually down-regulate phospho-VEGFR-2 levels through its inhibitory action of Wnt signaling.

MMPs are a family of zinc-dependent proteolytic endopeptidases with extracellular matrix remodeling and degrading properties [69]. They stimulate cancer cell growth, migration, invasion, angiogenesis and metastasis [13,33]. Among MMPs, MMP-9 is considered to play an important role in invasion and metastasis of cancer cells [70–76]. As γ -tocotrienol has been shown to remarkably inhibit angiogenesis of SGC-7901-CM-induced HUVECs, the activity of MMP-9 was further investigated in HUVECs. The results showed that γ -tocotrienol inhibited the protein expression of MMP-9 in a

dose-dependent manner. Thus, γ -tocotrienol may inhibit MMP-9 activity to suppress angiogenesis in HUVECs.

In summary, γ -tocotrienol inhibited proliferation, migration and tube formation in SGC-7901-CM-induced HUVECs and the new blood vessel formation *in vivo*. This suppression may partly involve the Wnt signaling pathway by down-regulation of β -catenin, cyclin D1, CD44, p-VEGFR-2 and MMP-9. These findings suggest that γ -tocotrienol may be a potential chemopreventive agent of cancer.

Acknowledgments

This project was supported by the National Natural Science Foundation of China (Nos. 81072296 and 30872105) and the Creative Foundation of Ph.D. Students of Harbin Medical University, P.R. China (No. HCXB2010012).

References

- [1] Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth *in vivo*. *Nature* 1993;362:841–4.
- [2] Miyazawa T, Shibata A, Sookwong P, Kawakami Y, Eitsuka T, Asai A, et al. Antiangiogenic and anticancer potential of unsaturated vitamin E (tocotrienol). *J Nutr Biochem* 2009;20:79–86.
- [3] Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* 1996;86:353–64.
- [4] Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE. Halting angiogenesis suppresses carcinoma cell invasion. *Nat Med* 1997;3:1222–7.
- [5] Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. *N Engl J Med* 1995;333:1757–63.
- [6] Ugurel S, Rapp G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. *J Clin Oncol* 2001;19:577–83.
- [7] Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. *J Natl Cancer Inst* 1994;86:356–61.
- [8] Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. *Ann Surg* 1972;175:409–16.
- [9] Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. *Nat Med* 2000;6:389–95.
- [10] Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. *Science* 1998;279:377–80.
- [11] Cao R, Wu HL, Veitonmaki N, Linden P, Farnebo J, Shi GY, et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. *Proc Natl Acad Sci U S A* 1999;96:5728–33.
- [12] Sacco MG, Cato EM, Ceruti R, Soldati S, Indraccolo S, Caniatti M, et al. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTV^{neu} transgenic mice. *Gene Ther* 2001;8:67–70.
- [13] Liu JR, Yang BF, Chen BQ, Yang YM, Dong HW, Song YQ. Inhibition of beta-ionone on SGC-7901 cell proliferation and upregulation of metalloproteinases-1 and -2 expression. *World J Gastroenterol* 2004;10:167–71.
- [14] McIntyre BS, Briski KP, Gapor A, Sylvester PW. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. *Proc Soc Exp Biol Med* 2000;224:292–301.
- [15] Gysin R, Azzi A, Visarius T. Gamma-tocopherol inhibits human cancer cell cycle progression and cell proliferation by down-regulation of cyclins. *FASEB J* 2002;16:1952–4.
- [16] Shah S, Gapor A, Sylvester PW. Role of caspase-8 activation in mediating vitamin E-induced apoptosis in murine mammary cancer cells. *Nutr Cancer* 2003;45:236–46.
- [17] Shun MC, Yu W, Gapor A, Parsons R, Atkinson J, Sanders BG, et al. Pro-apoptotic mechanisms of action of a novel vitamin E analog (alpha-TEA) and a naturally occurring form of vitamin E (delta-tocotrienol) in MDA-MB-435 human breast cancer cells. *Nutr Cancer* 2004;48:95–105.
- [18] Shah SJ, Sylvester PW. Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity. *Exp Biol Med (Maywood)* 2005;230:235–41.
- [19] Agarwal MK, Agarwal ML, Athar M, Gupta S. Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association. *Cell Cycle* 2004;3:205–11.
- [20] Xu WL, Liu JR, Liu HK, Qi GY, Sun XR, Sun WG, et al. Inhibition of proliferation and induction of apoptosis by gamma-tocotrienol in human colon carcinoma HT-29 cells. *Nutrition* 2009;25:555–66.
- [21] Srivastava JK, Gupta S. Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. *Biochem Biophys Res Commun* 2006;346:447–53.
- [22] Sakai M, Okabe M, Tachibana H, Yamada K. Apoptosis induction by gamma-tocotrienol in human hepatoma Hep3B cells. *J Nutr Biochem* 2006;17:672–6.

- [23] Sun W, Wang Q, Chen B, Liu J, Liu H, Xu W. Gamma-tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling. *Br J Nutr* 2008;99:1247–54.
- [24] Sun W, Xu W, Liu H, Liu J, Wang Q, Zhou J, et al. gamma-Tocotrienol induces mitochondria-mediated apoptosis in human gastric adenocarcinoma SGC-7901 cells. *J Nutr Biochem* 2009;20:276–84.
- [25] Bi S, Liu JR, Li Y, Wang Q, Liu HK, Yan YG, et al. gamma-Tocotrienol modulates the paracrine secretion of VEGF induced by cobalt(II) chloride via ERK signaling pathway in gastric adenocarcinoma SGC-7901 cell line. *Toxicology* 2010;274:27–33.
- [26] Miyazawa T, Inokuchi H, Hirokane H, Tsuzuki T, Nakagawa K, Igarashi M. Anti-angiogenic potential of tocotrienol in vitro. *Biochemistry (Mosc)* 2004;69:67–9.
- [27] Miyazawa T, Tsuzuki T, Nakagawa K, Igarashi M. Antiangiogenic potency of vitamin E. *Ann N Y Acad Sci* 2004;1031:401–4.
- [28] Nakagawa K, Shibata A, Yamashita S, Tsuzuki T, Kariya J, Oikawa S, et al. In vivo angiogenesis is suppressed by unsaturated vitamin E, tocotrienol. *J Nutr* 2007;137:1938–43.
- [29] Shibata A, Nakagawa K, Sookwong P, Tsuzuki T, Oikawa S, Miyazawa T. Tumor anti-angiogenic effect and mechanism of action of delta-tocotrienol. *Biochem Pharmacol* 2008;76:330–9.
- [30] Miyazawa T, Shibata A, Nakagawa K, Tsuzuki T. Anti-angiogenic function of tocotrienol. *Asia Pac J Clin Nutr* 2008;17(Suppl 1):253–6.
- [31] Liu JR, Li BX, Chen BQ, Han XH, Xue YB, Yang YM, et al. Effect of cis-9, trans-11-conjugated linoleic acid on cell cycle of gastric adenocarcinoma cell line (SGC-7901). *World J Gastroenterol: WJG* 2002;8:224–9.
- [32] Liu JR, Chen BQ, Yang YM, Wang XL, Xue YB, Zheng YM, et al. Effect of apoptosis on gastric adenocarcinoma cell line SGC-7901 induced by cis-9, trans-11-conjugated linoleic acid. *World J Gastroenterol: WJG* 2002;8:999–1004.
- [33] Chen BQ, Yang YM, Gao YH, Liu JR, Xue YB, Wang XL, et al. Inhibitory effects of c9, t11-conjugated linoleic acid on invasion of human gastric carcinoma cell line SGC-7901. *World J Gastroenterol: WJG* 2003;9:1909–14.
- [34] Liu HK, Wang Q, Li Y, Sun WG, Liu JR, Yang YM, et al. Inhibitory effects of gamma-tocotrienol on invasion and metastasis of human gastric adenocarcinoma SGC-7901 cells. *J Nutr Biochem* 2010;21(21):206–13.
- [35] Liu M, Liu RH, Song BB, Li CF, Lin LQ, Zhang CP, Zhao JL, Liu JR. Antiangiogenic effects of four varieties of grape in vitro. *J Food Sci* 2010;75:199–104.
- [36] Ribatti D, Vacca A, Ranieri G, Sorino S, Roncali L. The chick embryo chorioallantoic membrane as an in vivo wound healing model. *Pathol Res Pract* 1996;192:1068–76.
- [37] Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. *Nutr Cancer* 1992;18:1–29.
- [38] Liu JR, Dong HW, Chen BQ, Zhao P, Liu RH. Fresh apples suppress mammary carcinogenesis and proliferative activity and induce apoptosis in mammary tumors of the Sprague-Dawley rat. *J Agric Food Chem* 2009;57:297–304.
- [39] Liu JR, Sun XR, Dong HW, Sun CH, Sun WG, Chen BQ, et al. beta-Ionone suppresses mammary carcinogenesis, proliferative activity and induces apoptosis in the mammary gland of the Sprague-Dawley rat. *Int J Cancer* 2008;122:2689–98.
- [40] Liu JR, Dong HW, Sun XR, Wang Q, Sun WG, Parry JW, et al. Effects of beta-ionone on mammary carcinogenesis and antioxidant status in rats treated with DMBA. *Nutr Cancer* 2010;62:58–65.
- [41] Liu M, Lin LQ, Song BB, Wang LF, Zhang CP, Zhao JL, et al. Cranberry phytochemical extract inhibits SGC-7901 cell growth and human tumor xenografts in Balb/c nu/nu mice. *J Agric Food Chem* 2009;57:762–8.
- [42] Chen BQ, Xue YB, Liu JR, Yang YM, Zheng YM, Wang XL, et al. Inhibition of conjugated linoleic acid on mouse forestomach neoplasia induced by benzo (a) pyrene and chemopreventive mechanisms. *World J Gastroenterol: WJG* 2003;9:44–9.
- [43] Shao ZM, Wu J, Shen ZZ, Barsky SH. Genistein exerts multiple suppressive effects on human breast carcinoma cells. *Cancer Res* 1998;58:4851–7.
- [44] Zhou JR, Mukherjee P, Gugger ET, Tanaka T, Blackburn GL, Clinton SK. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. *Cancer Res* 1998;58:5231–8.
- [45] Yap SP, Yuen KH, Wong JW. Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. *J Pharm Pharmacol* 2001;53:67–71.
- [46] Osakada F, Hashino A, Kume T, Katsuki H, Kaneko S, Akaie A. Alpha-tocotrienol provides the most potent neuroprotection among vitamin E analogs on cultured striatal neurons. *Neuropharmacology* 2004;47:904–15.
- [47] Nesaretnam K, Guthrie N, Chambers AF, Carroll KK. Effect of tocotrienols on the growth of a human breast cancer cell line in culture. *Lipids* 1995;30:1139–43.
- [48] Ahn J, Gammon MD, Santella RM, Gaudet MM, Britton JA, Teitelbaum SL, et al. Myeloperoxidase genotype, fruit and vegetable consumption, and breast cancer risk. *Cancer Res* 2004;64:7634–9.
- [49] Wada S, Satomi Y, Murakoshi M, Noguchi N, Yoshikawa T, Nishino H. Tumor suppressive effects of tocotrienol in vivo and in vitro. *Cancer Lett* 2005;229:181–91.
- [50] Hiura Y, Tachibana H, Arakawa R, Aoyama N, Okabe M, Sakai M, et al. Specific accumulation of gamma- and delta-tocotrienols in tumor and their antitumor effect in vivo. *J Nutr Biochem* 2009;20:607–13.
- [51] Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. *Annu Rev Cell Dev Biol* 1998;14:59–88.
- [52] Akiyama T. Wnt/beta-catenin signaling. *Cytokine Growth Factor Rev* 2000;11:273–82.
- [53] Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. *Cell* 2000;103:311–20.
- [54] Polakis P. Wnt signaling and cancer. *Genes Dev* 2000;14:1837–51.
- [55] Polakis P. The many ways of Wnt in cancer. *Curr Opin Genet Dev* 2007;17:45–51.
- [56] Wright M, Aikawa M, Szeto W, Papkoff J. Identification of a Wnt-responsive signal transduction pathway in primary endothelial cells. *Biochem Biophys Res Commun* 1999;263:384–8.
- [57] Hanai J, Gloy J, Karumanchi SA, Kale S, Tang J, Hu G, et al. Endostatin is a potential inhibitor of Wnt signaling. *J Cell Biol* 2002;158:529–39.
- [58] Ishikawa T, Tamai Y, Zorn AM, Yoshida H, Seldin MF, Nishikawa S, et al. Mouse Wnt receptor gene Fzd5 is essential for yolk sac and placental angiogenesis. *Development* 2001;128:25–33.
- [59] Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. *J Biol Chem* 1997;272:24735–8.
- [60] Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. *J Cancer Res Clin Oncol* 2003;129:199–221.
- [61] Pennisi E. How a growth control path takes a wrong turn to cancer. *Science* 1998;281:1438–9, 1441.
- [62] Trochon V, Mabilat C, Bertrand P, Legrand Y, Smadja-Joffe F, Soria C, et al. Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. *Int J Cancer* 1996;66:664–8.
- [63] Weinberg RA. The retinoblastoma protein and cell cycle control. *Cell* 1995;81:323–30.
- [64] Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med* 2003;9:669–76.
- [65] Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. *Cancer Res* 2008;68:1843–50.
- [66] Xiao D, Singh SV. Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo. *Cancer Res* 2007;67:2239–46.
- [67] Lin CM, Chang H, Chen YH, Li SY, Wu IH, Chiu JH. Protective role of wogonin against lipopolysaccharide-induced angiogenesis in rat hepatic sinusoidal endothelial cells cross-stimulating the VEGF pathway. *Hepatology* 2008;47:1018–31.
- [68] Klein D, Demory A, Peyre F, Kroll J, Augustin HG, Helfrich W, et al. Wnt2 acts as a cell type-specific, autocrine growth factor in rat hepatic sinusoidal endothelial cells cross-stimulating the VEGF pathway. *Hepatology* 2008;47:1018–31.
- [69] Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. *Cancer Chemother Pharmacol* 1999;43(Suppl):S42–51.
- [70] Nagai S, Nakamura M, Yanai K, Wada J, Akiyoshi T, Nakashima H, et al. Gli1 contributes to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. *Cancer Sci* 2008;99:1377–84.
- [71] Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE. Androgen receptor and invasion in prostate cancer. *Cancer Res* 2008;68:1128–35.
- [72] Sun L, Diamond ME, Ottaviano AJ, Joseph MJ, Ananthanarayan V, Munshi HG. Transforming growth factor-beta 1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression. *Mol Cancer Res* 2008;6:10–20.
- [73] Lee SO, Jeong YJ, Kim M, Kim CH, Lee IS. Suppression of PMA-induced tumor cell invasion by capillaridin via the inhibition of NF-kappaB-dependent MMP-9 expression. *Biochem Biophys Res Commun* 2008;366:1019–24.
- [74] Kang JH, Han IH, Sung MK, Yoo H, Kim YG, Kim JS, et al. Soybean saponin inhibits tumor cell metastasis by modulating expressions of MMP-2, MMP-9 and TIMP-2. *Cancer Lett* 2008;261:84–92.
- [75] Cortes-Reynosa P, Robledo T, Macias-Silva M, Wu SV, Salazar EP. Src kinase regulates metalloproteinase-9 secretion induced by type IV collagen in MCF-7 human breast cancer cells. *Matrix Biol* 2008;27:220–31.
- [76] Moro L, Arbini AA, Yao JL, di Sant'Agnes PA, Marra E, Greco M. Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9. *Cancer Sci* 2008;99:553–63.